Table 1. Comparison of different assays to determine the effect of apigenin on LNCaP cell proliferation.
| 24 h | 48 h | 72 h | ||||
| Assays | Low dose* | High dose | Low dose | High dose | Low dose | High dose |
| Trypan blue | 84.6±6.7 | 53.8±7.0a | 65.7±4.1a b | 16.3±2.2a b | 58.2±3.9a b | 13.4±3.9a b |
| ATP | 84.9±5.8 | 55.6±7.0a | 68.8±3.3a b | 19.7±2.5a b | 60.3±5.8a b | 16.4±1.9a b |
| DNA | 83.6±8.9 | 63.6±6.5a | 67.4±2.1a b | 22.4±0.9a b | 59.3±9.2a b | 9.7±0.9a b |
| MTT | 81.6±3.5a | 58.6±2.1a | 68.2±3.5a b | 21.7±2.6a b | 64.2±7.0a b | 21.7±2.6a b |
| MTS | 85.6±4.2a | 50.3±2.2a | 68.6±5.0a b | 19.8±1.5a b | 64.2±6.0a b | 16.4±1.5a b |
* LNCaP cells were treated with apigenin at concentrations of 0 (DMSO), 15 µM (low dose), or 30 µM (high dose), and cell growth were assayed at desired time points. Values represent the percentage of viable cells compared to the vehicle (DMSO) control group and are presented in mean ± standard deviation.
a
compared to vehicle control, P<0.05;
b
compared to the 24 h value, P<0.05.